Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jan-Dec:18:17534666241304685.
doi: 10.1177/17534666241304685.

The effect of benralizumab on inflammation in severe asthma: a real-life analysis

Dina Visca  1   2 , Francesco Ardesi  1 , Martina Zappa  1 , Sarah Grossi  3 , Patrizia Pignatti  4 , Marco Vanetti  1   3 , Laura Pini  5   6 , Giovanni Sotgiu  7 , Rosella Centis  8 , Giovanni Battista Migliori  8 , Antonio Spanevello  1   3
Affiliations
Observational Study

The effect of benralizumab on inflammation in severe asthma: a real-life analysis

Dina Visca et al. Ther Adv Respir Dis. 2024 Jan-Dec.

Abstract

Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.

Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.

Design: This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients.

Methods: We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months.

Results: Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment (p < 0.0001) as well as an improvement in asthma control (p < 0.0001), health-related quality of life (p = 0.017) and lung function pre-BD FEV1 (L) (p = 0.02) and percentage (p = 0.004) and post-BD FEV1 (L) (p = 0.01) and percentage (p = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 (p < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = -0.79, p = 0.04). Moreover, the improvement of FEF25%-75% from baseline to 6 (rho = -0.53, p = 0.03) and 12 (rho = -0.62, p = 0.01) months negatively correlated with the duration of asthma disease.In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation.

Conclusion: Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission.

Keywords: airway inflammation; benralizumab; disease control; induced sputum; lung function; severe asthma.

Plain language summary

Analysis of the effect of a biological therapy on severe asthmaBackground: Asthma is estimated to affect almost 5%-8% of the European adult population, and 5%–10% of these patients suffer from a severe asthma form. Severe asthma is characterised by chronic airway inflammation despite traditional inhaled treatment and patients may experience acute flare ups requiring courses of steroids and eventually hospitalization leading to a poor quality of life. New biological drugs have been introduced to treat severe asthma characterized by inflammation in the blood and in the lungs. Benralizumab is a well known biological option for severe asthmatic patients.

Methods: We provide data on 22 patients followed up in our tertiary severe asthma centre in Tradate, Italy, affected by severe eosinophilic asthma treated with benralizumab for at least one year.

Results: Our data confirmed a rapid effect of benralizumab on respiratory symptoms, exacerbations and quality of life. In addition, we documented a significant improvement in lung function along with a normalization of inflammation in the blood and in the lungs, assessed with a non-invasive tool: the induced sputum.

Conclusions: Interestingly, our data highlight the importance of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Additional studies are needed to implement its role in the management of asthma also in terms of response to treatment towards a personalized approach.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Evolution of disease control (panels (a) and (b)) and health status (panel (c)) after 6 and 12 months of treatment in SEA with benralizumab: (a) ACT, (b) ACQ-6, (c) SGRQ. ***p < 0.0001. ACT, Asthma control test score; ACQ-6, asthma control questionnaire-6 score; SGRQ, St. George Questionnaire total score; SEA, severe eosinophilic asthma.
Figure 2.
Figure 2.
Evolution of airway eosinophilic inflammation (panel (a)) and lung function (panels (b) and (c)) after 6 and 12 months of treatment in SEA with benralizumab. (a) induced sputum (IS) eosinophils (%); (b) post-bronchodilator (BD) spirometry FEV1 (L); (c) post-bronchodilator (BD) spirometry FEF25%–75% (L/s). **p = 0.001***p < 0.0001; FEV1, forced expiratory volume in the first second; SEA, severe eosinophilic asthma.
See this image and copyright information in PMC

References

    1. Global Initiative for Asthma, GINA. 2024 GINA Report – Global Strategy for Asthma Management and Prevention, https://ginasthma.org/2024-report/ (2024, accessed May 15, 2024).
    1. Wecker H, Tizek L, Ziehfreund S, et al.. Impact of asthma in Europe: a comparison of web search data in 21 European countries. World Allergy Organ J 2023; 16(8): 100805. - PMC - PubMed
    1. Canonica GW, Colombo GL, Bruno GM, et al.. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J 2019; 12(1): 100007. - PMC - PubMed
    1. Schleich F, Brusselle G, Louis R, et al.. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108(12): 1723–1732. - PubMed
    1. Pelaia C, Busceti MT, Crimi C, et al.. Real-life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother 2020; 129: 110444. - PubMed

Publication types

MeSH terms